News

Pathios Therapeutics and Sygnature Discovery sign strategic partnership to discover novel GPR65 modulators for the treatment of autoimmune disease and cancer. Pathios Therapeutics,…
Read More...

Taiho Pharmaceuticaland Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Novelion Therapeutics Inc. announced that its subsidiary, Aegerion Pharmaceuticals has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. for the…
Read More...

Taiho Pharmaceutical and Cullinan Oncology announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered…
Read More...

Moderna, Inc., announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD)…
Read More...

The pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with…
Read More...

Trevi Therapeutics announced that it had entered into exclusive license agreements with Rutgers, The State University of New Jersey and MentiNova, Inc. for intellectual property and…
Read More...

IQVIA announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions…
Read More...

Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term…
Read More...

argenx and Halozyme Therapeutics announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE drug delivery technology to develop multiple…
Read More...

On February 1, 2019, GeneQuantum Healthcare of Suzhou and MITRO Biotech of Nanjing signed the "Strategic Cooperation Agreement on Next Generation Radionuclide Conjugates Development" in…
Read More...

Newron Pharmaceuticals announced the successful completion of patient enrollment in its STARS (Sarizotan for the Treatment of Apneas in Rett Syndrome) clinical study. Newron expects to…
Read More...

Alkermes plc announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for the…
Read More...

Hitachi Chemical Advanced Therapeutics Solutions, LLC announces an agreement by which apceth Biopharma GmbH, a contract manufacturer of cell and gene therapy products, will join Hitachi…
Read More...

Repare Therapeutics announced that it has entered into an exclusive strategic research, development and commercialization partnership with ONO Pharmaceutical Co., Ltd., for Repare’s…
Read More...

Alexion Pharmaceuticals, Inc. and Caelum Biosciences announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted…
Read More...

Invenra and WARF (Wisconsin Alumni Research Foundation) announced they have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of…
Read More...

Agenus Inc. announced the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare. Tokenization will enable qualified…
Read More...

Takeda Pharmaceutical announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization…
Read More...